Clinical Reviews in Allergy & Immunology

Clinical Reviews in Allergy and Immunology is a peer-reviewed journal founded by Humana Press in 1983 and today published on the Springer platform, devoted to scholarly reviews on the clinical management of allergic and immunologic diseases, with a 2025 Journal Impact Factor of 11.5（Clinical Reviews in Allergy & Immunology）是 1983 年由（Humana Press）创办、现于（Springer）平台出版的同行评审期刊，专注过敏与免疫性疾病临床管理的学术综述，2025 年影响因子为 11.5。

Scope

• It publishes scholarly reviews and experimental papers on the state of the art in managing allergic and immunologic diseases该刊发表关于过敏与免疫性疾病管理最新进展的学术综述与实验论文。
• It places newly available data into perspective for clinicians and researchers该刊把新近获得的数据置于完整脉络中加以解读。
• Each issue is devoted to a single theme of critical importance to allergists and immunologists该刊每期聚焦一个对过敏科与免疫学至关重要的单一主题。
• It elucidates the impact of novel data on clinical management against the background of standardized skin testing and challenge procedures该刊在标准化皮肤试验与激发试验方案等进展的背景下阐明新数据对临床管理的影响。
• Its in-depth reviews and experimental papers are written for a broad readership of immunologists该刊的深度综述与实验论文面向广大的免疫学读者群。
• Its stated objective is to help improve the care and management of patients with immune-mediated disease该刊的既定目标是帮助改善免疫介导疾病患者的照护与管理。
• It runs topical collections open for submissions on environmental allergies, dermatological allergies and food allergies该刊设有环境过敏、皮肤过敏与食物过敏等开放征稿的专题专辑。

History

• It was established in 1983 under the title Clinical Reviews in Allergy and took its present title in 1995该刊 1983 年以（Clinical Reviews in Allergy）之名创刊，1995 年改用现名。
• Volume numbering continued across the change, so the first volume under the present title was numbered thirteen in 1995改名时卷号延续，故现名首卷为 1995 年的第 13 卷。
• It now issues two volumes of three issues per year and reached its sixty-ninth volume in 2026该刊现在每年出版 2 卷共 6 期，2026 年已出版至第 69 卷。
• Recent thematic issues have covered COVID-19, autoantibodies, the primary immunodeficiencies, drug allergy and skin diseases近年专题期次涵盖（COVID-19）、自身抗体、原发性免疫缺陷、药物过敏与皮肤病等主题。
• Its Journal Impact Factor was 8.667 in 2021, 10.817 in 2022, 11.3 in 2024 and 11.5 in 2025, with a five-year value of 12.7 in 2025其影响因子 2021 年为 8.667，2022 年为 10.817，2024 年为 11.3，2025 年为 11.5，2025 年五年影响因子为 12.7。
• It ranks in the first quartile in both allergy and immunology, placing second among forty journals in allergy该刊在过敏与免疫学两类均居 Q1 区，并在过敏类别位列 2/40。

Editors

• Its editor-in-chief is Christopher Chang of the Memorial Healthcare System in Hollywood, Florida该刊主编为（Memorial Healthcare System）的（Christopher Chang）。
• Carlo Selmi of Humanitas University in Italy and Pascal Demoly of Montpellier are associate editors意大利（Humanitas University）的（Carlo Selmi）与蒙彼利埃的（Pascal Demoly）任副编辑。
• Mohamed Shamji of Imperial College London and Iris Otani of the University of California San Francisco are associate editors伦敦帝国理工学院的（Mohamed Shamji）与加州大学旧金山分校的（Iris Otani）任副编辑。
• Jinlyu Sun of Peking Union Medical College Hospital, Guogang Xu of the Chinese PLA General Hospital and Haijing Wu of the Second Xiangya Hospital are among its China-based editors北京协和医院的（Jinlyu Sun）、中国人民解放军总医院的（Guogang Xu）与湘雅二医院的（Haijing Wu）为该刊中国编辑。
• Rudolf Valenta of the Medical University of Vienna and Yehuda Shoenfeld of Reichman University serve on the editorial board维也纳医科大学的（Rudolf Valenta）与（Reichman University）的（Yehuda Shoenfeld）为编委。
• The board also includes Fu-Tong Liu of the Keck School of Medicine and Gil Yosipovitch of the University of Miami编委还包括（Keck School of Medicine）的（Fu-Tong Liu）与迈阿密大学的（Gil Yosipovitch）。